RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
Authors
Keywords
-
Journal
NATURE CELL BIOLOGY
Volume 20, Issue 9, Pages 1064-1073
Publisher
Springer Nature America, Inc
Online
2018-08-08
DOI
10.1038/s41556-018-0169-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- Large-Scale Phosphoproteomics Reveals Shp-2 Phosphatase-Dependent Regulators of Pdgf Receptor Signaling
- (2018) Tanveer S. Batth et al. Cell Reports
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer
- (2017) Takahiro Tashiro et al. PLoS One
- Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer
- (2016) A. J. Redig et al. CLINICAL CANCER RESEARCH
- Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
- (2016) Jorge Garcia Fortanet et al. JOURNAL OF MEDICINAL CHEMISTRY
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
- (2016) Ying-Nan P. Chen et al. NATURE
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
- (2016) M. P. Patricelli et al. Cancer Discovery
- BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
- (2015) Zhan Yao et al. CANCER CELL
- Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions
- (2015) S. Fujita-Sato et al. CANCER RESEARCH
- Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
- (2015) J. C. Hunter et al. MOLECULAR CANCER RESEARCH
- Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
- (2015) Michael Krauthammer et al. NATURE GENETICS
- PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs
- (2015) Anirudh Prahallad et al. Cell Reports
- Abstract 4289: 3-Dimensional growth reveals KRAS dependency.
- (2014) Rebecca Foster et al. CANCER RESEARCH
- Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
- (2014) Moriah H. Nissan et al. CANCER RESEARCH
- The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
- (2014) Ian R. Watson et al. CANCER RESEARCH
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Regulation of Hypoxia-inducible Factor 1α (HIF-1α) by Lysophosphatidic Acid Is Dependent on Interplay between p53 and Krüppel-like Factor 5
- (2013) Sei-Jung Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Oncogenic K-Ras requires activation for enhanced activity
- (2013) H Huang et al. ONCOGENE
- Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
- (2012) Piro Lito et al. CANCER CELL
- Identification of Mutant K-Ras-dependent Phenotypes Using a Panel of Isogenic Cell Lines
- (2012) Steffan Vartanian et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Fiji: an open-source platform for biological-image analysis
- (2012) Johannes Schindelin et al. NATURE METHODS
- Vemurafenib: the first drug approved for BRAF-mutant cancer
- (2012) Gideon Bollag et al. NATURE REVIEWS DRUG DISCOVERY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
- (2010) Matthias Drosten et al. EMBO JOURNAL
- Molecular and clinical analysis ofRAF1in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation
- (2010) Tomoko Kobayashi et al. HUMAN MUTATION
- Multiple Decisive Phosphorylation Sites for the Negative Feedback Regulation of SOS1 via ERK
- (2010) Yuji Kamioka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway
- (2007) Marie Dance et al. CELLULAR SIGNALLING
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More